Overhaul could cut UK brand prices 20%
This article was originally published in Scrip
Executive Summary
Prices of branded medicines used in the UK could undergo cuts of between 10% and 20%, according to a government consultation on proposals for changing the pricing of drugs used on the National Health Service.
You may also be interested in...
USCMA Revision Worsens Innovator Woes In Canada
Stripping the revised USMCA deal of provisions to strengthen IP rights for biologics will worsen market difficulties in Canada caused by changes to the drug pricing regime, says industry.
Calls to End Industry’s ‘Financial Entanglement’ With Healthcare Players
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
What’s Next After 20 Years Of NICE?
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports